Background: Vitiligo may impact psychosocial development, especially among African American pediatric patients, given heightened visibility and increasing rates of anxiety and depression in this subpopulation.
Objective: Evaluate psychiatric comorbidities and treatment initiation in African American pediatric patients.
Methods: A total of 327 African American pediatric patients with vitiligo were each matched to 3 patients without vitiligo by age, race, and sex in this case-control study. Prevalence of psychiatric conditions and subsequent initiation of pharmacotherapy and/or psychotherapy were analyzed.
Results: Compared to controls, pediatric African American patients with vitiligo were significantly more likely to be diagnosed with depression ( < .001) disruptive behavior disorders ( < .001), eating disorders ( = .013), generalized anxiety disorder ( < .001), substance abuse ( = .011), and suicidal ideation ( = .005). Patients with depression, disruptive behavior disorders, and eating disorders had higher initiation rates (76.5%, 82.1%, and 100%, respectively) for psychiatric treatment compared to those with generalized anxiety disorder and substance abuse (55.3% and 61.5%). Nearly 15% of patients did not initiate treatment for suicidal ideation.
Limitations: This retrospective study has a limited sample size in a single institution and does not explore psychiatric treatment efficacy.
Conclusions: Better understanding of associated psychological comorbidities and impacts on African American children of vitiligo may improve quality of life and dermatologic outcomes for these individuals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471237 | PMC |
http://dx.doi.org/10.1016/j.jdin.2024.07.012 | DOI Listing |
Front Immunol
January 2025
Genentech, Inc., South San Francisco, CA, United States.
Objectives: This case series describes adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.
Methods: Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.
Taxon Rep Int Lepid Surv
October 2023
Department of Biophysics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9050, USA.
Genomic sequencing of worldwide butterfly fauna followed by phylogenetic analysis of protein-coding genes informs butterfly classification throughout the taxonomic hierarchy, from families to species. As a rule, we attribute the same taxonomic rank to more prominent clades of comparable divergence (i.e.
View Article and Find Full Text PDFJ Patient Exp
January 2025
Equity and Inclusion for the Department of Neurology and Psychiatry and Behavioral Neurosciences, Wayne State University, Livonia, MI, USA.
The mental health workforce in the United States faces a significant challenge: a stark underrepresentation of African American practitioners. This disparity reflects broader issues of racial inequality in healthcare and has far-reaching implications for mental health care delivery, particularly within Black communities. This perspective examines the contributing factors to this underrepresentation, explores its consequences on patient care and research, and proposes strategies to increase diversity in the field.
View Article and Find Full Text PDFElucidating the genetic contributions to Parkinson's disease (PD) etiology across diverse ancestries is a critical priority for the development of targeted therapies in a global context. We conducted the largest sequencing characterization of potentially disease-causing, protein-altering and splicing mutations in 710 cases and 11,827 controls from genetically predicted African or African admixed ancestries. We explored copy number variants (CNVs) and runs of homozygosity (ROHs) in prioritized early onset and familial cases.
View Article and Find Full Text PDFMultiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative disease affecting the brain and spinal cord. Genetic studies have identified many risk loci, that were thought to primarily impact immune cells and microglia. Here, we performed a multi-ancestry genome-wide association study with 20,831 MS and 729,220 control participants, identifying 236 susceptibility variants outside the Major Histocompatibility Complex, including four novel loci.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!